Given known associations and likely bidirectional contribution of type 2 diabetes to NASH phenotypes (43), we speculate that increased hepatocyte-derived MCP-1 may have systemic impact in other metabolically active tissues (i.e., adipose, muscle), but this requires further study. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.